Company news
Soligenix, Inc. (NASDAQ:SNGX) news
Soligenix, Inc. news releases on 6ix. Latest, Jan 16, 2025: Soligenix to Present at Upcoming Investor Conferences
Press releases — page 2
Soligenix to Present at Upcoming Investor Conferences
January 15, 2025
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
January 13, 2025
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
December 16, 2024
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
December 15, 2024
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
December 1, 2024
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
November 18, 2024
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
November 14, 2024
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
November 13, 2024
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
November 7, 2024
Soligenix Announces Participation at the Spartan Capital Investor Conference
October 28, 2024
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
October 23, 2024
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
October 21, 2024
Soligenix Invited to Present at Upcoming Investor Conferences
October 15, 2024
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
October 6, 2024
Soligenix Announces Partnership with Sterling Pharma Solutions
October 2, 2024
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
September 15, 2024
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
September 2, 2024
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
August 8, 2024
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
July 8, 2024
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
June 24, 2024
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
June 13, 2024
Soligenix Announces Reverse Stock Split
May 30, 2024
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
May 28, 2024
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
May 23, 2024
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
May 22, 2024
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
May 20, 2024
Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
May 19, 2024
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
May 15, 2024
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
May 9, 2024
Soligenix to Present at Upcoming Conferences
May 5, 2024
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
April 24, 2024
Soligenix Announces Pricing of $4.75 Million Public Offering
April 17, 2024
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
April 14, 2024
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
April 10, 2024
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
April 2, 2024
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
March 14, 2024
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
February 7, 2024
Soligenix to Present at The Microcap Conference
January 24, 2024
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
January 7, 2024
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
January 1, 2024
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
November 29, 2023
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
November 12, 2023
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
September 24, 2023
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
September 21, 2023
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
August 20, 2023
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
August 9, 2023
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
July 10, 2023
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
May 15, 2023
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
May 14, 2023
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
May 10, 2023